NTT Electronics starts shipping 140 Gbaud High-performance Coherent DSP
6.3.2023 21:00:00 EET | Business Wire | Press release
NTT Electronics, a leading supplier of coherent Digital Signal Processor (DSP) solutions to system and module manufacturers worldwide, today announced start of 140 Gbaud high-performance coherent DSP (ExaSPEED GAIA) shipment to customers. ExaSPEED GAIA achieves world's largest transmission capacity of 1.2 Tbit/s per wavelength by utilizing a programmable baud rate of up to 140 Gbaud powered by a flexible coded modulation scheme and advanced 5nm FinFET CMOS process.
“We are excited to add the ExaSPEED GAIA DSP to our product portfolio which cuts the power consumption per bit to half while doubling the baud rate over earlier product offering,” said Satoshi Shigematsu, NTT Electronics General Manager of Broadband System & Device Business Unit. “We believe this high-performance DSP will help our customers offer highly differentiated optical transmission equipment and systems”, he added.
The programmable baud rate can support very fine granularity that enables ExaSPEED GAIA to adapt to a range of links while maximizing spectral efficiency. These include short-reach data center interconnects (DCI), terrestrial metro links with cascaded ROADMs, and ultra-long-haul sub-sea links. Customers can use a wide range of 400G interfaces in 1.2T (3x400GbE) for DCI, 800G (2x400GbE) for metro and 400G (1x400GbE) for sub-sea applications. This capability helps simplify interfaces and optimize Capital/Operational expenditure. Moreover, ExaSPEED GAIA also offers fine capacity tuning in 50G increments to respond to various customer requirements.
Flexible coded modulation is the newly-developed coding scheme to efficiently implement advanced constellation shaping, forward error correction (FEC), and high-order modulation format with high performance and low power. This enables ExaSPEED GAIA to support thousands of operational modes that cover a multitude of customer's transmission links with high energy efficiency. To enhance the performance, ExaSPEED GAIA employs a number of novel compensation algorithms including nonlinear distortion compensation, adaptive fast state of polarization (SOP) tracking, fast device and transmission characteristics estimation, and ultra-long CD compensation for high-baud rate systems*. The performance of ExaSPEED GAIA can be further optimized by combining it with NTT Electronics’ industry-leading high speed coherent driver module (UHB-CDM).
"We are very impressed with the performance of NTT Electronics’ latest ExaSPEED GAIA DSP," commented Hideki Matsui, Vice Head of Photonics System Business Unit, Fujitsu Limited. “This revolutionary DSP makes our products more competitive in the market and enables us to offer innovative solutions. It opens up a new 'terabit era,' which will be a game changer in our industry,” he added.
“This state-of-the-art DSP, we believe would be key to realize the future information-centric society,” said Akio Goto, General Manager of Photonics Device Development Division, NEC Corporation. He also said, “We are excited to introduce ExaSPEED GAIA in conjunction with CDM in our DWDM products to build diverse, high-throughput and green optical networks.”
* https://group.ntt/en/newsrelease/2022/09/05/220905a.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005007/en/
Contact information
NTT Electronics Contact :
Atul Srivastava, CEO & CTO
NTT Electronics America, Inc.
Tel : +1-201-556-1770
Email : pr@nel-america.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom